Medifast Statistics
Total Valuation
Medifast has a market cap or net worth of $141.69 million. The enterprise value is -$8.30 million.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Medifast has 10.34 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | 10.34M |
| Shares Outstanding | 10.34M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | -0.32% |
| Owned by Insiders (%) | 2.62% |
| Owned by Institutions (%) | 73.36% |
| Float | 9.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.28 |
| Forward PS | 0.38 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | 10.52 |
| P/OCF Ratio | 6.88 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.07.
| Current Ratio | 3.52 |
| Quick Ratio | 2.72 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.61 |
| Debt / FCF | 1.09 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -3.32% and return on invested capital (ROIC) is 1.69%.
| Return on Equity (ROE) | -3.32% |
| Return on Assets (ROA) | 1.33% |
| Return on Invested Capital (ROIC) | 1.69% |
| Return on Capital Employed (ROCE) | 2.82% |
| Revenue Per Employee | $1.08M |
| Profits Per Employee | -$13,883 |
| Employee Count | 504 |
| Asset Turnover | 1.87 |
| Inventory Turnover | 3.31 |
Taxes
| Income Tax | -275,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.60% in the last 52 weeks. The beta is 0.89, so Medifast's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -31.60% |
| 50-Day Moving Average | 13.12 |
| 200-Day Moving Average | 15.94 |
| Relative Strength Index (RSI) | 52.84 |
| Average Volume (20 Days) | 277,707 |
Short Selling Information
The latest short interest is 1.33 million, so 12.87% of the outstanding shares have been sold short.
| Short Interest | 1.33M |
| Short Previous Month | 1.15M |
| Short % of Shares Out | 12.87% |
| Short % of Float | 14.49% |
| Short Ratio (days to cover) | 6.15 |
Income Statement
In the last 12 months, Medifast had revenue of $543.45 million and -$7.00 million in losses. Loss per share was -$0.64.
| Revenue | 543.45M |
| Gross Profit | 401.58M |
| Operating Income | 6.18M |
| Pretax Income | 37.29M |
| Net Income | -7.00M |
| EBITDA | 18.90M |
| EBIT | 6.18M |
| Loss Per Share | -$0.64 |
Full Income StatementBalance Sheet
The company has $164.59 million in cash and $14.61 million in debt, giving a net cash position of $149.98 million or $14.50 per share.
| Cash & Cash Equivalents | 164.59M |
| Total Debt | 14.61M |
| Net Cash | 149.98M |
| Net Cash Per Share | $14.50 |
| Equity (Book Value) | 210.96M |
| Book Value Per Share | 20.40 |
| Working Capital | 152.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $20.60 million and capital expenditures -$7.14 million, giving a free cash flow of $13.47 million.
| Operating Cash Flow | 20.60M |
| Capital Expenditures | -7.14M |
| Free Cash Flow | 13.47M |
| FCF Per Share | $1.30 |
Full Cash Flow StatementMargins
Gross margin is 73.89%, with operating and profit margins of 1.14% and -1.29%.
| Gross Margin | 73.89% |
| Operating Margin | 1.14% |
| Pretax Margin | -1.34% |
| Profit Margin | -1.29% |
| EBITDA Margin | 3.48% |
| EBIT Margin | 1.14% |
| FCF Margin | 2.48% |
Dividends & Yields
Medifast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.04% |
| Shareholder Yield | -0.04% |
| Earnings Yield | -4.94% |
| FCF Yield | 9.50% |
Dividend DetailsAnalyst Forecast
The average price target for Medifast is $16.50, which is 20.44% higher than the current price. The consensus rating is "Hold".
| Price Target | $16.50 |
| Price Target Difference | 20.44% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medifast has an Altman Z-Score of 5.4 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.4 |
| Piotroski F-Score | 5 |
